Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells

被引:89
作者
Spiekermann, K
Pau, M
Schwab, R
Schmieja, K
Franzrahe, S
Hiddemann, W
机构
[1] Univ Munich, Hosp Grosshadern, Dept Med 3, D-81377 Munich, Germany
[2] GSF Munich, Clin Cooperat Grp Leukemia, D-81377 Munich, Germany
关键词
D O I
10.1016/S0301-472X(01)00787-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Signal transducers and activators of transcription (STAT) factors are critical mediators in the signal transduction of cytokine receptors. In hematopoietic and epithelial cells, activation of STAT 1 induces apoptosis and growth arrest, whereas activation of STAT3 and STAT5 transduces growth-promoting signals. We and others have previously described a high expression and constitutive activation of STAT1, 3, and 5 in AML blasts. In this report we focused on the mechanisms and also the biologic relevance of STAT activation in AML. Results. We report here that a constitutive STAT activation can be detected in up to 95% of primary AML blasts. In vitro, neither induction of the leukemic fusion protein PML-RARalpha in U937 cells nor expression of transforming ras-mutants, but several leukemic protein tyrosine kinase (PTK), strongly induced activation of STAT3 and 5. Stable transfection of BA/F3 cells with TEL-JAK2, TEL-ABL, and BCR-ABL resulted in IL-3 independent growth and strong activation of STAT3 and STAT5 by TEL-JAK2 and TEL-ABL, but not by BCR-ABL. In addition, expression of constitutive active mutants of STAT3 and STAT5 alone were sufficient to transform BA/F3 cells. Conclusions. These results show that STAT3 and STAT5 are activated in the majority of primary AML blasts and are major targets of leukemic fusion proteins with PTK activity. However, the STAT activation pattern by leukemic PTKs differed signficantly and might reflect their transforming potential in acute (TEL-JAK2 and TEL-ABL) and chronic leukemias (p210BCR-ABL). The transforming capacity of constitutively activated STAT3 and STAT5 mutants strongly supports their fundamental role in the process of malignant transformation in hematopoietic cells. (C) 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:262 / 271
页数:10
相关论文
共 46 条
[21]  
ILHOAN O, 2000, BLOOD, V275
[22]   Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice [J].
Kaplan, DH ;
Shankaran, V ;
Dighe, AS ;
Stockert, E ;
Aguet, M ;
Old, LJ ;
Schreiber, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7556-7561
[23]   Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product [J].
Kiyoi, H ;
Towatari, M ;
Yokota, S ;
Hamaguchi, M ;
Ohno, R ;
Saito, H ;
Naoe, T .
LEUKEMIA, 1998, 12 (09) :1333-1337
[24]   STAT signaling in the pathogenesis and treatment of leukemias [J].
Lin, TS ;
Mahajan, S ;
Frank, DA .
ONCOGENE, 2000, 19 (21) :2496-2504
[25]   Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways [J].
Mizuki, M ;
Fenski, R ;
Halfter, H ;
Matsumura, I ;
Schmidt, R ;
Müller, C ;
Grüning, R ;
Kratz-Abers, K ;
Serve, S ;
Steur, C ;
Büchner, T ;
Kienast, J ;
Kanakura, Y ;
Berdel, WE ;
Serve, H .
BLOOD, 2000, 96 (12) :3907-3914
[26]   STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells [J].
Nosaka, T ;
Kawashima, T ;
Misawa, K ;
Ikuta, K ;
Mui, ALF ;
Kitamura, T .
EMBO JOURNAL, 1999, 18 (17) :4754-4765
[27]   Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation [J].
Onishi, M ;
Nosaka, T ;
Misawa, K ;
Mui, ALF ;
Gorman, D ;
McMahon, M ;
Miyajima, A ;
Kitamura, T .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (07) :3871-3879
[28]   Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia [J].
Peeters, P ;
Raynaud, SD ;
Cools, J ;
Wlodarska, I ;
Grosgeorge, J ;
Philip, P ;
Monpoux, F ;
VanRompaey, L ;
Baens, M ;
VandenBerghe, H ;
Marynen, P .
BLOOD, 1997, 90 (07) :2535-2540
[29]   Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? [J].
Reuter, CWM ;
Morgan, MA ;
Bergmann, L .
BLOOD, 2000, 96 (05) :1655-1669
[30]   HUMAN FLT3/FLK2 GENE - CDNA CLONING AND EXPRESSION IN HEMATOPOIETIC-CELLS [J].
ROSNET, O ;
SCHIFF, C ;
PEBUSQUE, MJ ;
MARCHETTO, S ;
TONNELLE, C ;
TOIRON, Y ;
BIRG, F ;
BIRNBAUM, D .
BLOOD, 1993, 82 (04) :1110-1119